Reviva Pharmaceuticals Secures European Patent for Brilaroxazine

An announcement from Reviva Pharmaceuticals Holdings (RVPH) is now available.

Reviva Pharmaceuticals Holdings, Inc. has announced the issuance of a European patent for their drug brilaroxazine for treating pulmonary hypertension, expanding their intellectual property portfolio across major markets including the US, China, and Japan. The patent encompasses treatment for all pulmonary hypertension patients and specifically for those with chronic obstructive pulmonary disease or sickle cell disease. Additionally, brilaroxazine has been recognized with Orphan Drug Designation in the US for pulmonary arterial hypertension.

For a thorough assessment of RVPH stock, go to TipRanks’ Stock Analysis page.